Mumbai, October 30, 2025 – Cipla Ltd. today announced its financial results for the second quarter of the fiscal year 2025-26 (Q2FY26), reporting a consolidated net profit of ₹1,353.37 crore, a 3.7% increase compared to ₹1,302.53 crore in the corresponding quarter last year. The pharmaceutical giant also revealed that Achin Gupta, currently the Global Chief Operating Officer (GCOO), will succeed Umang Vohra as the Managing Director (MD) and Global Chief Executive Officer (GCEO), effective April 1, 2026.
The company's total revenue from operations for the quarter stood at ₹7,589.44 crore, marking a 7.63% surge from ₹7,051.02 crore in Q2FY25. Total expenses for the quarter were ₹6,004.86 crore, compared to ₹5,452.57 crore in the same period last year.
Cipla's Q2 performance was driven by robust growth in its key markets. The India business demonstrated resilience, fueled by branded prescriptions and trade generics. North America maintained steady momentum, supported by a stable market share in Albuterol and new product launches. Emerging markets and South Africa also contributed to the company's growth, aided by a recovery in institutional business and favorable currency movements.
Umang Vohra, the current MD and Global CEO of Cipla, has decided not to seek reappointment upon the completion of his current term on March 31, 2026. Achin Gupta, who joined Cipla in 2021 and was appointed as GCOO in February 2025, will take over the role on April 1, 2026, for a term of five years, up to March 31, 2031. Gupta holds an M.Tech degree from IIT Delhi and an MBA from IIM Ahmedabad and brings over two decades of experience as an entrepreneurial leader. Before fully assuming his new role, Gupta will be designated as MD & GCEO-Designate on January 1, 2026.
The company also announced that Meera Vanjari will become the Global General Counsel and Senior Management Personnel from April 1, 2026, succeeding A.S. Kumar.
"I am pleased to share that we continue to make considerable progress across our focused markets," said Umang Vohra. "In Q2FY26, we delivered our highest-ever quarterly revenue of ₹7,589 crore, with a robust EBITDA margin of 25%. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets".
Vohra highlighted the 7% year-on-year growth in Cipla's "One-India business" and the launch of Yurpeak (Tirzepatide) as a "pivotal step into obesity care" through their strategic partnership with Eli Lilly. The U.S. business posted revenue of $233 million during the quarter.
Cipla is also planning to launch four major respiratory assets by 2026, including gAdvair in Q4 FY26. Three peptide assets, including Liraglutide, are also in the pipeline.
Cipla's Bommasandra manufacturing facility in Bengaluru was classified as VAI (Voluntary Action Indicated) by the USFDA during the quarter, a key regulatory milestone supporting future U.S. launches.
While near-term margin pressures may persist, analysts believe Cipla is well-positioned for sustainable growth across its key markets. At last check, Cipla shares were down 0.40 per cent at Rs 1,574.50 following the earnings announcement.
